Preview

Neurology, Neuropsychiatry, Psychosomatics

Advanced search

Search


Order results by:     
 
Issue Title
 
Vol 3, No 4 (2011) Parkinson's disease fatigability and its correction with the dopamine receptor agonist pramipexole Abstract  similar documents
Marina Romanovna Nodel
"... therapy with the dopamine receptor agonist pramipexole (Mirapex). Patients and methods ..."
 
Vol 4, No 1 (2012) Sustained-release pramipexole in the treatment of Parkinson’s disease Abstract  similar documents
Natalia Vladimirovna Fedorova
"... for dopaminergic deficiency in Parkinson’s disease (PD). Since 1996, pramipexole has been used to treat early ..."
 
Vol 4, No 2 (2012) Capacities of the dopamine receptor agonist pramipexole in the treatment of patients with Parkinson’s disease Abstract  similar documents
S N Illarioshkin
"... receptor agonists (DRA) remains the leading pharmacotherapeutic strategy for Parkinson’s disease (PD ..."
 
Vol 6, No 3 (2014) Current therapy for Parkinson's disease Abstract  similar documents
A. V. Obukhova
"... -release pramipexole formulations contain the same active ingredient and have the same dopamine-receptor ..."
 
Vol 3, No 1 (2011) Sleep disorders in Parkinson's disease Abstract  similar documents
Marina Romanovna Nodel', Marina Romanovna Nodel
"... of Parkinson's disease (PD). Objective: to specify the clinical features of sleep disorders in patients with PD ..."
 
Vol 6, No 1 (2014) Apathy in Parkinson's disease patients Abstract  similar documents
M. R. Nodel
"... pathy in Parkinson's disease (PD) patients is one of the least studied manifestations of a broad ..."
 
Vol 4, No 3 (2012) Clinical experience with requip modutab Abstract  similar documents
Denis Valeryevich Zakharov, V A Mikhailov
"... The efficacy of dopamine receptor agonists (DRAs) is determined by a number of advantages. DRAs ..."
 
Vol 5, No 3 (2013) The efficacy of the dopamine agonist Rotigotine in the treatment of Parkinson's disease Abstract  similar documents
Marina Romanovna Nodel
"... Rotigotine is a new, non-ergot dopamine receptor agonist (DRA) formulated as a transdermal drug ..."
 
Vol 2, No 3 (2010) Treatment of parkinson's disease ata young age Abstract  similar documents
Dmitry Valeryevich Artemyev
"... and middle-aged patients. It is stressed that early-onset Parkinson's disease (PD) shows a number ..."
 
Vol 6, No 2S (2014): Special issue "Stroke" NMDA receptor antagonists in the treatment of patients with vascular cognitive imprairments Abstract  similar documents
I.S. Preobrazhenskaya
"... The paper discusses the possibilities of using the NMDA receptor antagonist memantine in patients ..."
 
Vol 4, No 2 (2012) Sigma receptors: their role in the treatment of affective disorders  similar documents
V E Medvedev
"... . Огромный интерес вызвал доклад проф. K. Hashimoto (Япония), посвященный изучению роли сигма-рецепторов в ..."
 
Vol 5, No 1 (2013) Practical aspects of the use of extended-release ropinirole (requip modutab) in the treatment of Parkinson’s disease Abstract  similar documents
Oleg Semenovich Levin, V K Datiyeva
"... receptor agonist (DRAs), which has been widely used to treat Parkinson’s disease (PD) in foreign countries ..."
 
Vol 5, No 1 (2013) Dopamine dysregulation syndrome in Parkinson’s disease Abstract  similar documents
A V Nikitina, Natalia Vladimirovna Fedorova
"... therapy. According to the data available in the literature, DDS develops in 3-4% of the Parkinson’s ..."
 
Vol 2, No 4 (2010) Depression in Parkinson's disease Abstract  similar documents
Marina Romanovna Nodel', Marina Romanovna Nodel
"... Parkinson's disease (PD) is a multisystemic neurodegenerative disease with a wide spectrum ..."
 
Vol 3, No 1 (2011) Heart rhythm variability analysis in patients with Levy body dementiaand in those with Parkinson's disease Abstract  similar documents
I G Tishkova, Irina Sergeevna Preobrazhenskaya, I G Tishkova, Irina Sergeyevna Preobrazhenskaya
"... ) and Parkinson's disease (PD). Objective: to analyze autonomic provision of cardiac performance in patients ..."
 
Vol 4, No 1 (2012) Sleep and awakening disorders in Parkinson’s disease: comprehensive approach to therapy Abstract  similar documents
Marina Romanovna Nodel
"... and awakening disorders in patients with Parkinson’s disease (PD). It covers the current views of the role ..."
 
Vol 1, No 2 (2009) NERVOUS AND MENTAL DISORDERS OF PARKINSON'S DISEASE Abstract  similar documents
Marina Romanovna Nodel', N N Yakhno, Marina Romanovna Nodel, N N Yakhno
"... Parkinson's disease (PD) is a multisystemic neurodegenerative disease involving different mediator ..."
 
Vol 10, No 2 (2018) Current management tactics for patients with dementia Abstract  similar documents
A. V. Medvedeva, O. V. Kosivtsova, K. A. Makhinov
"... inhibitors and N-methyl-D-aspartate (NMDA) glutamate receptor antagonists. Atypical neuroleptics are employed ..."
 
Vol 9, No 4 (2017) Sleep disorders in Parkinson’s disease: approaches to treatment and prevention Abstract  similar documents
M. R. Nodel, G. V. Kovrov
"... Nocturnal sleep disorders are one of the most important non-motor manifestations of Parkinson’s ..."
 
Vol 8, No 4 (2016) HYPERSOMNIA AND CIRCADIAN DISTURBANCES IN PARKINSON’S DISEASE Abstract  similar documents
M. R. Nodel
"... studied symptoms of Parkinson’s disease (PD). It manifests as constant excessive sleepiness during the day ..."
 
Vol 7, No 3 (2015) Experience in using levodopa-benserazide Abstract  similar documents
Elena Anatolyevna Katunina, Yu. N. Bezdolnyi, E. A. Malykhina, N. V. Titova
"... Levodopa remains the most effective drug for the treatment of Parkinson's disease. The paper ..."
 
Vol 6, No 4 (2014) Nondrug therapy in the combination rehabilitation of patients with Parkinson’s disease Abstract  similar documents
V. L. Golubev, A. B. Kamakinova
"... Non-drug rehabilitation in Parkinson’s disease (PD) has recently attracted the increasing ..."
 
Vol 5, No 2 (2013) The clinical picture of early-stage Parkinson’s disease. errors in the diagnosis of different forms Abstract  similar documents
E N Gubanova, Natalia Vladimirovna Fedorova
"... The paper describes the clinical picture of Parkinson’s disease (PD), by indicating its stages ..."
 
Vol 9, No 1 (2017) The clinical features, diagnosis, and treatment of cognitive impairments in Parkinson's disease Abstract  similar documents
G. N. Akhmadeeva, R. V. Magzhanov, G. N. Tayupova, A. R. Baitimerov
"... with Parkinson's disease (PD) and gives their characteristics and epidemiology, the specific features ..."
 
Vol 10, No 4 (2018) Approaches to therapy for depressions in neurology: prospects for the use of agomelatine Abstract  similar documents
D. V. Romanov, B. A. Volel, D. S. Petelin
"... in neurological practice. The drug has a unique receptor profile, being a melatonin receptor type 1 and 2 agonist ..."
 
Vol 10, No 4 (2018) Nighttime sleep disorders in patients with daytime sleepiness in Parkinson s disease Abstract  similar documents
M. R. Nodel, K. V. Shevtsova, G. V. Kovrov, N. N. Yakhno
"... Daytime sleepiness is one of the clinically significant non-motor manifestations of Parkinson ..."
 
Vol 10, No 2 (2018) Parkinson's disease and polymorphisms of the glutamatergic system genes GRIN2A, SLC1A2, and GRIK4 Abstract  similar documents
Yu. S. Mironova, I. A. Zhukova, N. G. Zhukova, S. A. Ivanova, V. M. Alifirova, A. S. Boiko, D. Z. Osmanova, O. P. Izhboldina, A. V. Latypova
"... kainate receptor. Patients and methods. Examinations were made in 222 patients diagnosed with Parkinson ..."
 
Vol 8, No 2 (2016) Alzheimer's disease under the mask of stroke Abstract  similar documents
A. A. Naumenko, N. V. Vakhnina
"... and vascular CIs are acetylcholinesterase inhibitors and N-methyl-D-aspartate receptor antagonists ..."
 
Vol 8, No 4 (2016) ALZHEIMER’S DISEASE: DIAGNOSIS AND TREATMENT Abstract  similar documents
A. A. Naumenko, D. O. Gromova, N. V. Trofimova, I. S. Preobrazhenskaya
"... -рецепторов; акатинол мемантин; гантенерумаб; нооторопная терапия; церебролизин; нелекарственные методы ..."
 
Vol 10, No 4 (2018) Cognitive and motor training for patients with moderate cognitive impairment and mild dementia Abstract  similar documents
A. A. Naumenko, I. S. Preobrazhenskaya
 
Vol 5, No 2 (2013) Current possibilities of therapy for sleep disorders in Parkinson’s disease Abstract  similar documents
Marina Romanovna Nodel
"... and awakening disorders in patients with Parkinson's disease (PD). It covers the current views of the role ..."
 
Vol 4, No 1 (2012) Association of the dopamine receptor (DRD4, DAT) gene polymorphisms with vital exhaustion in an open population among 25—64-year-old men (Novosibirsk): Epidemiological study according to the WHO MONICA-psychosocial program Abstract  similar documents
Valery Vasilyevich Gafarov, M I Voyevoda, E A Gromova, V N Maksimov, A V Gafarova, I V Gagulin, N S Yudin, T M Mishakova
"... of Medical Sciences (Novosibirsk). Results. The genotype containing allele 7 in the dopamine receptor subtype ..."
 
Vol 11, No 3S (2019): Спецвыпуск: когнитивные нарушения, цереброваскулярные заболевания Non-drug therapies for cognitive impairment Abstract  similar documents
I. S. Preobrazhenskaya, D. Fantalis, S. A. Abdyshova, A. A. Kindarova
 
Vol 5, No 4 (2013) Dementia: epidemiology, clinical picture, diagnosis, approaches to therapy Abstract  similar documents
Irina Sergeyevna Preobrazhenskaya
"... to the pathogenetic therapy for dementia and the efficiency and safety of using NMDA receptor antagonists in patients ..."
 
Vol 7, No 4 (2015) Some aspects of treatment for cognitive impairments. Cyticolin: pharmacological characteristics, possible benefits, aspects of use Abstract  similar documents
N. V. Trofimova, I. S. Preobrazhenskaya
"... ; neuroprotective effect; sirtuins; Alzheimer’s disease; Parkinson’s disease. Contact: Irina Sergeevna ..."
 
Vol 3, No 3 (2011) Neuropsychiatrie disorders in Parkinson's disease and their correction with the MAO-B inhibitor rasagiline (Azilect®) Abstract  similar documents
M R Nodel
"... Parkinson's disease (PD) is a multisystemic neurodegenerative disease with a broad spectrum ..."
 
Vol 9, No 2 (2017) Chemoreactomic analysis of thiamine disulfide, thiamine hydrochloride, and benfotiamine molecules Abstract  similar documents
O. A. Gromova, I. Yu. Torshin, L. V. Stakhovskaya, L. E. Fedotova
"... that thiamine disulfide can inhibit the molecular receptors involved in blood pressure regulation: adrenoceptors ..."
 
Vol 6, No 4 (2014) The epidemiological, clinical, and genetic characteristics of Parkinson’s disease (in case of Zheleznogorsk) Abstract  similar documents
M. R. Sapronova, N. A. Shnaider
"... Parkinson’s disease (PD) is the second most common human neurodegenerative disorder. Genetically ..."
 
Vol 9, No 1 (2017) The genetic basis of Parkinson's disease Abstract  similar documents
A. A. Tappakhov, T. E. Popova, T. Ya. Nikolaeva, P. I. Gurieva, N. A. Shnaider, M. M. Petrova, M. R. Sapronova
"... Parkinson's disease (PD) is a multifactorial disease that develops in the presence of both genetic ..."
 
Vol 9, No 4 (2017) Neuropsychological pattern of Parkinson's disease Abstract  similar documents
A. A. Tappakhov, T. E. Popova, T. Ya. Nikolaeva, N. A. Schnaider, M. M. Petrova, M. R. Sapronova
"... The review deals with the problem of neuropsychological disorders in Parkinson's disease (PD), one ..."
 
Vol 10, No 2 (2018) Molecular mechanisms of action of glucosamine sulfate in the treatment of degenerative-dystrophic diseases of the joints and spine: results of proteomic analysis Abstract  similar documents
O. A. Gromova, I. Yu. Torshin, A. M. Lila, A. N. Gromov
"... and discussion. GS interacts with the receptors CD44, TLR4, and ICAM1 on the surface of chondrocytes, inhibits ..."
 
Online-first Features of pathogenesis and clinical manifestation of Parkinson's disease developed from essential tremor Abstract  similar documents
A. V. Kudrevatykh, I. V. Miliukhina
"... In last decades, there is evidence of the relationship of Parkinson's disease (PD) and essential ..."
 
Vol 11, No 2 (2019) Pathogenesis, clinical features, and treatments of depression in Parkinson's disease Abstract  similar documents
I. V. Milyukhina
"... Depression is the most common non-motor manifestation of Parkinson's disease (PD), which ..."
 
Vol 4, No 1 (2012) Antyhypertensive therapy-based secondary prevention of ischemic stroke Abstract  similar documents
Vladimir Anatolyevich Parfenov, S V Verbitskaya, Yu A Starchina
"... ischemic attack. The possible neuroprotective effects of angiotensin II receptor blockers are discussed ..."
 
Vol 8, No 3 (2016) Systematic analysis of basic and clinical studies of etifoxine Abstract  similar documents
I. Yu. Torshin, O. A. Gromova, V. A. Semenov, T. R. Grishina
"... . The anxiolytic effect of etifoxine is due, firstly, to the modulation of GABA receptor activity and, secondly ..."
 
Vol 9, No 1 (2017) The triple synergy of ethylmethylhydroxypyridine succinate, magnesium, and vitamin B6: Molecular mechanisms Abstract  similar documents
O. A. Gromova, A. G. Kalacheva, I. Yu. Torshin, T. R. Grishina, I. K. Tomilova
"... and neuromuscular transmission, to reduce anxiety, by activating acetylcholine, GABA, and dopamine receptors ..."
 
Vol 5, No 1 (2013) Blood pressure lowering-based prevention and the POWER trial Abstract  similar documents
Vladimir Anatolyevich Parfenov, S V Verbitskaya
"... results of the POWER trial evaluating the safety and efficacy of eprosartan, an angiotensin receptor ..."
 
Vol 5, No 2S (2013): Special issue "Stroke" Management of patients with post-stroke dementia Abstract  similar documents
Svetlana Viktorovna Verbitskaya
"... the efficacy of central acetylcholinesterase inhibitors and the NMDA receptor antagonist akatinol memantine ..."
 
Vol 5, No 2 (2013) Neuropsychological syndromes in patients with Parkinson’s disease after deep electric stimulation of pallidar complex structures Abstract  similar documents
Yu V Mikadze, Irina Igorevna Titkova, A O Gushcha, V M Tyurnikov
"... The paper provides the results of neuropsychological examinations in 10 patients with Parkinson’s ..."
 
Vol 8, No 3 (2016) Chemoreactome analysis of ethylmethylhydroxypyridine succinate Abstract  similar documents
O. A. Gromova, I. Yu. Torshin, L. E. Fedotova, A. N. Gromov
"... of acetylcholine and GABA receptors, as well as that of cannabinoid receptor type 2. The anti-inflammatory effect ..."
 
1 - 50 of 293 Items 1 2 3 4 5 6 > >> 

Search tips:

  • Search terms are case-insensitive
  • Common words are ignored
  • By default articles containing any term in the query are returned (i.e., OR is implied)
  • Make sure that a word exists in an article by prefixing it with +; e.g., +journal +access scholarly academic
  • Combine multiple words with AND to find articles containing all terms; e.g., education AND research
  • Exclude a word by prefixing it with - or NOT; e.g., online -politics or online NOT politics
  • Search for an exact phrase by putting it in quotes; e.g., "open access publishing". Hint: Quoting Chinese or Japanese words will help you to find exact word matches in mixed-language fields, e.g. "中国".
  • Use parentheses to create more complex queries; e.g., archive ((journal AND conference) NOT theses)